C3J Therapeutics is a privately-held, clinical-stage biotechnology company focused on the discovery and development of novel targeted antimicrobials – synthetic bacteriophage (phage) and antimicrobial peptides.
C3J is the worldwide, exclusive licensee from UCLA of the STAMP (Specifically Targeted Antimicrobial Peptides) Platform which mines bacterial genomes for targeting domains that confer pathogen-specific killing activity. To date, C3J has raised $137 million to develop our lead molecule (C16G2) and to expand our technological approach to target pathogens, including use of phage or phage structures that confer selective killing.
In February 2018, we acquired an engineered phage platform to complement our antimicrobial peptide platform and combat the rapidly growing problem of multidrug-resistant bacterial infections (read the Press Release). Our asset purchase also included a partnered program with a U.S.-based global pharmaceutical company, as well as a lead synthetic phage product candidate for Pseudomonas aeruginosa infections.
C3J’s 35,000 square foot facility in Los Angeles, California, has state-of-the-art microbiology labs dedicated to the discovery of novel targeted antimicrobials. R&D capabilities are also in place for phage/peptide production and purification, as well as drug product formulation capabilities for oral, topical, luminal, and parenteral dosage forms for both phage and peptides. The facility is equipped with GMP drug manufacturing suites (licensed by California Department of Public Health) enabling production, purification, and release of clinical trial material.